CJC-1295 Peptide Therapy in Alpharetta

What CJC-1295 is

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hormone that signals the pituitary gland to secrete growth hormone. It is chemically engineered to bind serum albumin, which extends its activity in the body well beyond that of natural GHRH. CJC-1295 is not FDA approved for any indication and is not a growth hormone product itself.

The compound exists in two forms discussed in the research and commercial literature: one with a chemical modification called Drug Affinity Complex (DAC) that binds albumin covalently, and one without it, sometimes labeled "CJC-1295 no DAC," which behaves more like a shorter-acting GHRH analogue. The published pharmacokinetic study cited in this page used the DAC-bearing version. Products marketed as "no DAC" are pharmacologically closer to a different, shorter-half-life molecule, and the two should not be assumed to share identical evidence.

How it is thought to work

By binding albumin, CJC-1295 is designed to resist rapid breakdown and continue stimulating GHRH receptors in the pituitary over an extended window, reported at roughly 8 to 10 days in one pharmacokinetic study (Teichman et al., 2006, PubMed). The proposed mechanism is a prolonged, mild elevation of growth hormone pulsatility rather than a large spike, distinguishing it from direct growth hormone administration.

Because it works upstream, at the level of the pituitary rather than by supplying growth hormone directly, researchers have proposed that CJC-1295 preserves the body's natural pulsatile secretion pattern rather than overriding it. That is a meaningfully different pharmacological approach from injecting growth hormone itself, and it is the basis for interest in GHRH analogues generally, including tesamorelin, the one member of this drug class with a genuine FDA approval.

What the research shows

The clearest human data comes from a study of 11 healthy young men (ages 20 to 34, BMI under 25) who received a single subcutaneous dose of CJC-1295. Researchers measured serum growth hormone and IGF-1 across a 12-hour overnight sampling window before dosing and again one week later, and found statistically significant increases in both mean growth hormone and IGF-1 levels, with the natural pulsatile pattern of GH secretion preserved (Jetté et al., 2005, Activation of the GH/IGF-1 axis by CJC-1295, PMC). A related pharmacokinetic paper further characterized the compound's extended half-life in circulation (Teichman et al., 2006, PubMed).

These are real, published human findings, and we want to be precise about their scope: they measured hormone concentrations in a small sample over about a week, not downstream outcomes such as muscle mass, body fat, sleep quality, or cognitive function. No controlled trial establishing those broader claims for CJC-1295 has been published to our knowledge, and research suggests such claims should currently be treated as unproven extrapolation rather than fact.

We also have not identified controlled human trials of CJC-1295 combined with a ghrelin-receptor agonist such as ipamorelin, despite that combination being widely marketed as a paired protocol. Each compound has its own separate, limited evidence base; combining two under-studied compounds does not generate new evidence for the pair, and no trial has measured what that specific combination does in humans.

What it is not

CJC-1295 is not FDA approved, and it is not equivalent to prescription growth hormone therapy or to tesamorelin, the only GHRH analogue that has cleared FDA review, and only for a specific approved indication. It is not a validated treatment for muscle building, fat loss, anti-aging, or sleep, despite how it is frequently marketed alongside other growth hormone secretagogues. The early-phase study behind it involved 11 subjects for about one week — that scale does not support broad wellness claims, and it should not be described as clinically proven on the strength of a single small pharmacokinetic study.

It is also not a substitute for a full hormonal workup. Growth hormone and IGF-1 are only two markers within a broader endocrine picture that includes thyroid function, sex hormones, and metabolic markers, all of which shape how a person actually feels day to day.

How Aeon approaches it

We treat CJC-1295 as a compound with a genuine, but narrow, human pharmacokinetic dataset rather than a validated wellness protocol. If hormonal optimization or recovery is your goal, our clinical team can review your case alongside relevant clinic lab and hormone therapy options during a consultation, so any decision is grounded in what has actually been measured rather than in extrapolated marketing claims.

That conversation typically starts with baseline diagnostics rather than a compound decision, because knowing where your growth hormone, IGF-1, and broader endocrine markers actually sit is more useful than assuming a GHRH analogue is the right lever before the numbers say so.